Patients with immune thrombocytopenia in remission after treatment may still experience a relapse of the disease, depending on individual circumstances.
Immune thrombocytopenia is an acquired autoimmune bleeding disorder, mainly characterized by thrombocytopenia of the peripheral blood with no obvious cause, and may be associated with bleeding from the skin and mucous membranes, severe visceral bleeding and even intracranial bleeding.
The first-line treatment for immune thrombocytopenia includes the use of high-dose dexamethasone, prednisone, and intravenous infusion of gammaglobulin, while the second-line treatment includes the use of pro-platelet-generating drugs such as eltrombopag, rituximab, and splenectomy. All of these treatment options should be used under medical supervision.
Some patients respond well to conventional treatment and achieve complete remission, but some patients experience treatment failure or relapse after remission.
Relapse of immune thrombocytopenia mainly refers to the platelet count dropping below 30 x 10^9/L or the development of bleeding symptoms after effective treatment. It should be treated aggressively depending on the individual.
Diagnosis and treatment of specific diseases need to be under the guidance of a physician.